Boston, MA, United States of America

Raul Mostoslavsky

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2010-2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Raul Mostoslavsky

Introduction

Raul Mostoslavsky is a prominent inventor based in Boston, MA (US), known for his significant contributions to the field of cancer research. With a focus on pancreatic ductal adenocarcinomas (PDAC), he has developed innovative methods and agents that aim to improve treatment outcomes for patients suffering from this aggressive form of cancer. His work has led to the filing of three patents, showcasing his commitment to advancing medical science.

Latest Patents

Mostoslavsky's latest patents revolve around the critical role of NAD-dependent histone deacetylase SIRT6 in the suppression of PDAC. His research has revealed that SIRT6 controls the expression of Lin28b, a negative regulator of let-7 microRNA. The loss of SIRT6 results in histone hyperacetylation at the Lin28b promoter, leading to the recruitment of Myc and the subsequent induction of Lin28b and downstream let-7 target genes, including HMGA2, IGF2BP1, and IGF2BP3. These inventions relate to agents and methods aimed at reducing the expression or activity of Lin28b to treat aggressive PDAC in subjects.

Career Highlights

Throughout his career, Raul Mostoslavsky has worked with esteemed organizations such as the General Hospital Corporation and Children's Medical Center Corporation. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Mostoslavsky has had the opportunity to work alongside notable colleagues, including Sita Kugel and Anders M Naar. These collaborations have further enriched his research and innovation efforts.

Conclusion

Raul Mostoslavsky's work in the field of cancer research, particularly regarding pancreatic ductal adenocarcinomas, highlights his innovative spirit and dedication to improving patient care. His patents and collaborations reflect a commitment to advancing medical science and finding effective treatments for challenging diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…